Senti Biosciences(US:SNTI)2026-03-27 12:01Financial Performance - Senti Bio reported a net loss of $14.5 million, or $0.53 per share, for Q4 2025, and a full-year net loss of $61.4 million, or $2.73 per share[6]. - Total operating expenses for the full year 2025 were $68.8 million, compared to $61.0 million in 2024[15]. - The accumulated deficit increased to $358.6 million as of December 31, 2025, from $297.1 million in 2024[13]. - Senti Bio's total assets were reported at $51.2 million as of December 31, 2025, down from $97.8 million in 2024[13]. Research and Development - Research and development expenses for Q4 2025 were $7.8 million, consistent with Q4 2024, while total R&D expenses for the full year 2025 were $37.6 million, up from $34.4 million in 2024[5][15]. - The company received Regenerative Medicine Advanced Therapy (RMAT) designation for SENTI-202 for treating adults with relapsed or refractory acute myeloid leukemia (AML)[5]. - Positive preliminary clinical data from the ongoing Phase 1 trial of SENTI-202 showed encouraging response rates and a favorable safety profile[5]. General and Administrative Expenses - General and administrative expenses decreased to $5.8 million in Q4 2025 from $8.4 million in Q4 2024, with full-year G&A expenses totaling $26.2 million[5][15]. Cash Position - As of December 31, 2025, Senti Bio had cash and cash equivalents of approximately $16.4 million, down from $48.3 million in 2024[5][13]. Strategic Focus - The company is focused on advancing its Gene Circuit platform and key development milestones to deliver innovative therapies for serious diseases[2].